Bpifrance

Ecoat develops and manufactures bio‑based binders and coatings that reduce the carbon footprint of the paint and coating industry. Its product line includes water‑based, bio‑based alkyd emulsions, tension‑free specialty oils, and urethane‑modified alkyd emulsions, as well as air‑purifying emulsions and other specialty products such as secoia and inokem. The company supplies these sustainable binders to manufacturers of architectural, wood, and metal protective coatings, allowing them to produce eco‑friendly paints and varnishes without sacrificing performance.

MSInsight is a bioinformatics startup specializing in the development of diagnostic and treatment response prediction solutions for microsatellite instability (MSI) cancers. The company offers a platform that utilizes next-generation sequencing data to analyze MSI status, a crucial biomarker in oncology. By providing actionable insights on this biomarker, MSInsight enables healthcare professionals to make informed decisions about patient care, particularly concerning treatment options such as immunotherapy. The focus on diagnostic and prognostic biomarkers of treatment response enhances the ability to improve overall patient outcomes in the oncology market.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Mabqi, headquartered in Grabels, France, is a biopharmaceutical company specializing in immunotherapy. It operates an antibody discovery platform, enabling the identification and development of innovative, proprietary therapeutic molecules.

EG 427 is a French biotechnology company specializing in gene therapy. It pioneers 'pinpoint gene therapy', focusing on HSV-1-based vectors to treat severe, chronic, and localized diseases, with an initial focus on neurogenic bladder disorders resulting from spinal cord injuries.

Superbranche is a biotechnology company specializing in the early detection and treatment of metastases. It develops therapeutic and diagnostic applications using nanotechnological provisions, aiming to improve accessibility and enable early tumor detection.

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Its platform enables targeted delivery of therapeutic genes to the CNS, enhancing autophagy and lysosomal function, with a focus on improving patient outcomes for conditions like ALS.

NEBULA maps 3D macromolecule using dataset-free genAI and physics, enhancing drug target discovery, which forms the basis of all new drugs.

BiPER Therapeutics is a biotechnology company focused on developing innovative therapeutics, particularly targeting key proteins involved in cancer cell survival and treatment resistance. Its primary focus is on gastrointestinal cancers.

Biomemory is a deep-tech company focusing on innovative data storage solutions for large enterprises and institutions. It leverages molecular engineering to create cost-effective, energy-efficient appliances that enable exabyte-scale storage. The company's advanced data storage drives utilize a biobased system that encodes substantial amounts of data on long DNA strands, significantly surpassing the capacity of traditional storage methods such as solid-state drives and magnetic tapes. Biomemory's technology offers remarkable durability, ensuring data stability at ambient temperatures without the need for energetic input or CO2 emissions, making it an environmentally friendly choice. This approach provides researchers and organizations with a long-lasting storage solution, capable of preserving information for thousands of years.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on the clinical development of first-in-class drug candidates aimed at treating and preventing diseases affecting pets, including periodontitis, osteoarthritis, and gut motility disorders. By prioritizing the creation of effective treatments for common health issues, Vetbiolix aims to enhance the quality of life for pets and their owners.

Orakl Oncology specializes in expediting cancer drug discovery by employing advanced biology and AI-driven analysis. It maintains a unique collection of patient tumor avatars, integrating biological and clinical data, to create realistic tumor models that mimic real-life drug responses. By mining multi-modal experimental data and combining it with deep patient data, Orakl enables oncology companies to identify relevant targets and develop more effective treatments at an accelerated pace.

Meiogenix is a biotechnology company developing breeding technologies to uncover unexplored genetic diversity in organisms, expanding natural biodiversity and enabling the development of products to address global food, climate, sustainability, and industrial challenges. It uses chromosome-editing-based approaches to modulate the frequency of homologous recombination in eukaryotic cells, enabling natural breeding and delivering new products for farmers and industry.

Afyren is a sustainable chemistry company focused on developing innovative biotechnological solutions that utilize non-food biomass to replace petroleum-based ingredients. Committed to environmental sustainability, Afyren employs natural microorganisms to produce a range of bio-sourced organic acids and a high-value fertilizer. The company's approach aligns with the principles of a circular, low-carbon economy, emphasizing the valorization of biomass while minimizing environmental impact. Through its advancements, Afyren aims to contribute to the transition toward greener and more sustainable industrial practices.

Lactips produces biodegradable thermoplastic pellets derived from milk protein. These pellets are used by clients as a sustainable alternative to oil-based products in various plastic applications.

Faircraft develops a lab‑grown alternative to animal leather using synthetic biology, material science, and tissue engineering. The company produces a cell‑based material that offers the same mechanical strength and durability as premium leather while eliminating animal slaughter. By culturing cells in controlled environments, Faircraft reduces carbon dioxide emissions and provides a sustainable, cruelty‑free option for the fashion and upholstery industries.

Primaa is a MedTech company that provides an AI-powered platform for automated cancer diagnosis. Through image analysis and deep learning, the software enhances the detection of cancer biomarkers and supports personalized treatment decisions. It offers digital histology capabilities that digitize tissue slides, aggregate images in a database, and enable digital identification of tissue anomalies. The platform aims to increase diagnostic accuracy and throughput while maintaining consistent reliability across histological assessments.

Elicit Plant is an agro-biotech company focused on enhancing crop resilience to water scarcity. It develops innovative phytosterol-based solutions that significantly reduce water stress in plants, enabling them to better withstand drought conditions.

Theremia is a health technology company that leverages artificial intelligence to transform drug development, with a focus on neurological disorders. It employs advanced machine learning to optimize drug compounds for specific demographic groups, enhancing treatment effectiveness and reducing adverse effects.

Fudzs specializes in sustainable bioeconomy, developing eco-friendly cell bioproduction processes using cutting-edge bioreactor technology. By integrating advanced biomaterial engineering with cellular science, Fudzs enables mass production of cells at reduced costs, opening new market opportunities.

Founded in 2016, Vaxinano is a biotechnology company dedicated to the preclinical and pharmaceutical development of human and veterinary vaccines. It specializes in creating vaccines and drug delivery systems that selectively target difficult pathogens like parasites, viruses, or bacteria.

Starfish Bioscience specializes in developing biotechnological systems for agriculture and viticulture. Its primary focus is regenerating soil health by restoring microbiomes, enhancing sustainability and crop yields, while minimizing environmental impact.

Okomera is a biotech start-up focused on enhancing access to more effective, precision-based cancer therapies. The company has pioneered the automation and miniaturization of individualized tumor biopsy research, developing advanced medical technologies that leverage microfluidic 3D cellular assays. These innovative technologies enable the prediction of patient-specific responses to cancer treatments by automating relevant biopsy testing. In this process, tumor cells are cultivated within thousands of microfluidic droplets and exposed to numerous conditions simultaneously. This approach allows healthcare providers to expedite the development and delivery of modern cancer therapies, ultimately improving treatment outcomes for patients.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on the clinical development of first-in-class drug candidates aimed at treating and preventing diseases affecting pets, including periodontitis, osteoarthritis, and gut motility disorders. By prioritizing the creation of effective treatments for common health issues, Vetbiolix aims to enhance the quality of life for pets and their owners.

Enalees develops molecular diagnostic tests for animals that can be used directly by veterinarians, enabling rapid on-site detection of infectious diseases in pets and livestock. The company provides fast, easy-to-use diagnostic kits with integrated reagents and a portable reader, designed for use in clinics and field settings to support timely and accurate treatment decisions.

Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants utilizing its innovative miPEP technology, which harnesses naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep focuses on four key development programs: germination, flowering, growth, and weed control, aiming to improve agricultural yields while maintaining the integrity of plant DNA. By leveraging the potential of these biomimetic peptides, Micropep seeks to provide effective solutions for managing plant genetics and enhancing resistance to diseases, thereby supporting sustainable farming practices.

GenoMines is a company focused on sustainable mining through innovative biological methods. It specializes in using plant-based technologies to extract critical metals from soils that are below traditional cut-off grades. By genetically enhancing hyperaccumulator plants, GenoMines leverages nature's ability to absorb metals, thereby not only sustainably mining these resources but also depolluting soils and increasing the availability of agricultural sites. This approach addresses significant environmental and societal challenges associated with conventional mining methods, aiming to support the transition to green energy in a responsible manner.

StarkAge Therapeutics is a discovery-stage biotechnology company focused on improving the quality of life for patients through innovative treatments. The company specializes in developing a platform that utilizes immunotherapy combined with cancer therapy to target and deplete senescent cells associated with age-related diseases. Its research and development efforts are aimed at addressing conditions such as idiopathic pulmonary fibrosis, neurodegenerative diseases, and metabolic dysfunctions, including hepatic fibroses. By leveraging its unique approach, StarkAge Therapeutics seeks to provide effective therapeutic options for managing these challenging health issues.

Biodol Therapeutics develops first-in-class therapies for chronic pain by targeting the FLT3 receptor, a receptor tyrosine kinase expressed on sensory neurons that triggers and sustains neuropathic pain. The company advances extracellular inhibitors of FLT3 to block ligand binding and disrupt pain signaling, with goals to reduce allodynia, hypersensitivity and spontaneous pain while preserving normal nervous system function. By pairing FLT3 inhibition with opioid analgesia, Biodol Therapeutics aims to enhance pain relief and potentially lower opioid-related safety risks. Founded in 2015 and based in Clapiers, France, the company collaborates with academic researchers to validate FLT3 as a therapeutic target for chronic pain.

MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.

Hephaistos Pharma is a biotechnology company developing an immunotherapy platform aimed at producing advanced oncology treatments. Its platform enhances commercialized antibodies by stimulating the immune system, turning 'cold' tumors into targets for immune response.

Tribun Health specializes in digital health solutions for cancer detection. It develops innovative systems that enable diagnostic laboratories and pharmaceutical/biotech companies to manage, analyze, and share cellular images efficiently.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Surge is a biotechnology company dedicated to enhancing surgical outcomes for patients. It has developed an advanced immunological model known as Surge2surgery, which predicts postoperative infections. This innovative platform integrates a single-cell analysis of the immune system conducted prior to surgery with clinical data, utilizing a proprietary machine-learning algorithm. By examining millions of immune cells from a small blood sample, Surge's technology simulates surgical trauma in a controlled environment, allowing for improved predictions and potentially better patient care.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

HawkCell specializes in advanced magnetic resonance imaging (MRI) solutions for veterinary clinics and preclinical research labs. Utilizing non-ionizing, three-dimensional MRI technology adapted for diverse animal morphologies, the company offers sustainable systems enhanced by artificial intelligence algorithms to provide precise and insightful animal healthcare services.

Bioptimus develops a universal AI foundation model that connects biological data across different scales, from molecules to entire organisms. This enables clients to derive actionable insights and accelerate biomedical innovation.

Okomera is a biotech start-up focused on enhancing access to more effective, precision-based cancer therapies. The company has pioneered the automation and miniaturization of individualized tumor biopsy research, developing advanced medical technologies that leverage microfluidic 3D cellular assays. These innovative technologies enable the prediction of patient-specific responses to cancer treatments by automating relevant biopsy testing. In this process, tumor cells are cultivated within thousands of microfluidic droplets and exposed to numerous conditions simultaneously. This approach allows healthcare providers to expedite the development and delivery of modern cancer therapies, ultimately improving treatment outcomes for patients.

Founded in Paris, France in 2014, Eligo Bioscience specializes in developing innovative antimicrobials called Eligobiotics. These are protein-based nanodelivery vectors that employ a synthetic circuit encoding for a programmable RNA-guided nuclease, targeting bacteria based on their genome. The company's applications span therapeutics, cosmetics, biodefense, and more.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates engineered viral vector vaccines for cancer treatment. The company's innovative platform leverages a portfolio of modified viral vectors, specifically designed for the efficient expression of long strings of tumor neoantigens. This approach is complemented by a toolkit that facilitates the induction of robust antitumor T-cell responses, effectively enhancing cancer-specific cellular immunity in patients. Through its research and development efforts, Nouscom aims to improve cancer treatment outcomes by harnessing the body's immune system to target and combat cancer cells.

Astraveus is developing the Lakhesys platform, an end-to-end cell foundry for cell and gene therapy manufacturing. The platform uses deep process optimization and single-use microfluidic bioprocessors to produce autologous therapies with reduced inputs and infrastructure needs, lowering costs and logistical barriers. By enabling automated, patient-specific biomanufacturing, Astraveus aims to improve access to transformative CGTs. The system builds equipment tailored for each patient to use autologous cells, leveraging microfluidic chip technology to convert cells into therapeutic agents. The approach seeks to scale production of cell and gene therapies while minimizing environmental impact and resource use, supporting more sustainable manufacturing at lower cost.

Osiris Agriculture is a technology company focused on sustainable farming. It develops autonomous, four-wheeled robots designed to assist farmers in growing potatoes, sugar beets, and field crops. These robots automate and enhance tasks such as watering, fertilizing, weeding, and crop protection, aiming to improve agricultural sustainability and help farmers optimize their operations.

Global Bioenergies SA specializes in developing a biological process that converts renewable resources into isobutene, a crucial petrochemical building block used in fuels, plastics, organic glass, and elastomers. The company, based in Evry, France, is notable for being one of the few globally and the only one in Europe focusing on this innovative fermentation technology. It operates an industrial pilot plant and is nearing the completion of a demonstration plant in Germany, alongside preparing for its first full-scale production facility in collaboration with Cristal Union, known as IBN-One. In addition to isobutene, Global Bioenergies has expanded its capabilities to include the production of propylene and butadiene, both vital components in the petrochemical sector. The company was founded in 2008 and continues to enhance the efficiency of its processes while offering engineering services related to gas fermentation.

Global Bioenergies SA specializes in developing a biological process that converts renewable resources into isobutene, a crucial petrochemical building block used in fuels, plastics, organic glass, and elastomers. The company, based in Evry, France, is notable for being one of the few globally and the only one in Europe focusing on this innovative fermentation technology. It operates an industrial pilot plant and is nearing the completion of a demonstration plant in Germany, alongside preparing for its first full-scale production facility in collaboration with Cristal Union, known as IBN-One. In addition to isobutene, Global Bioenergies has expanded its capabilities to include the production of propylene and butadiene, both vital components in the petrochemical sector. The company was founded in 2008 and continues to enhance the efficiency of its processes while offering engineering services related to gas fermentation.

Diamidex SAS, established in 2014 and based in Marseille, France, specializes in the development and production of rapid detection tests for legionella, a type of bacteria that can cause severe lung infections. The company offers turnkey test solutions, designed for both laboratory and field use, which provide semi-quantitative counts of microorganisms in water samples and industrial goods. Diamidex's products aim to enhance the accuracy and speed of microbial contamination detection, facilitating more efficient screening and data collection in research and testing environments.

EverImmune specializes in developing live biotherapeutic products designed to enhance the efficacy of immunotherapy for cancer patients. Its flagship product, Oncobax®, aims to restore responsiveness to immune checkpoint inhibitors by leveraging gut microbiota.

Toopi Organics is a biotechnology company based in Langon, France, established in 2019. It develops microbiological and agricultural technologies to transform human urine into fertilizers and biostimulants for agriculture. The company collects and upcycles human urine, depollutes and enriches it with microorganisms to provide natural, economical, and efficient alternatives to chemical fertilizers. Its products include Arbop and Vitip, which support plant growth and crop health, offering farming communities an environmentally conscious option for nutrient supply.

Tribun Health specializes in digital health solutions for cancer detection. It develops innovative systems that enable diagnostic laboratories and pharmaceutical/biotech companies to manage, analyze, and share cellular images efficiently.

Phagos develops personalized bacteriophage solutions as a sustainable alternative to antibiotics.

BioMAdvanced Diagnostics is a company focused on developing molecular diagnostic and biomarker tests that enhance patient care through individualized treatment strategies. Their innovative tests are designed to integrate seamlessly into existing diagnostic and treatment protocols, ensuring ease of use for healthcare personnel. By providing predictive scores and identifying biomarkers, BioMAdvanced Diagnostics enables clinicians to assess the immune response of patients and evaluate the risk of transplant rejection. This capability allows for improved anticipation and adaptation of treatment plans, ultimately aiming to enhance patient outcomes significantly.

GenSensor is a biotechnology company that specializes in developing and implementing a genomic-based, in-line bioproduction monitoring system. This system combines a robotic device with advanced analytics software to monitor, characterize, and optimize the production of advanced therapy medicinal products (ATMPs) and vaccines. By providing real-time insights into the bioproduction process, GenSensor helps healthcare companies maximize the use of innovative drugs, improve production efficiency, and ultimately reduce manufacturing costs, thereby benefiting patients.

SFE Process specializes in the design and manufacture of laboratory equipment, particularly focusing on extraction machines that utilize supercritical fluids. The company develops innovative and modular pressure equipment, providing tailored laboratory systems that cater to a variety of applications. By offering flexible and multipurpose extraction systems, SFE Process enables its clients to efficiently achieve their objectives in diverse research and industrial settings.

Numa Health is a medical bioinformatics health technology company that focuses on empowering individuals to optimize their health capital and well-being. It has developed a digital health platform that offers tools designed to enhance users' commitment to their health. This platform facilitates the reinterpretation of blood test results, providing insights into bodily functions and overall health. By enabling users to measure, understand, and take actionable steps regarding their health, Numa Health aims to support individuals in their journey towards better health management.

Veragrow is a manufacturing company specializing in the production of organic fertilizers and biostimulants. The company utilizes vermicomposting to transform agricultural waste products into valuable resources. Veragrow's offerings provide an alternative to chemical fertilizers, focusing on revitalizing soil health and increasing yields in organic farming while respecting local fauna and flora.

Kairos Discovery is a biotechnology company focused on developing novel targeted cancer therapies. Its mission is to create innovative medicinal chemistry solutions that aim to transform the lives of cancer patients.

Founded in 2011, Ynsect is a biotech company specializing in insect farming and processing. It produces feed for fish and poultry using insects as a sustainable protein source. The company also develops products for non-food applications such as organic fertilizers and bioenergy.

Odimma is a biotech company specializing in precision medicine aimed at developing personalized cancer immunotherapy solutions. The company has created an innovative immunotherapy drug that harnesses a unique platform, integrating three specific immune components designed to work together with the patient's immune system. When administered, this approach aims to induce and enhance immune responses, providing patients with the potential to eliminate tumors while minimizing adverse side effects. Through its focus on personalized treatment strategies, Odimma seeks to improve outcomes for cancer patients by tailoring therapies to individual needs.

Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.

Hemerion Therapeutics specializes in developing innovative cancer treatments, with a primary focus on advanced methods for treating glioblastoma, the most common and aggressive form of primary brain tumour. The company's proprietary platform combines photosensitizing molecules with advanced laser light technologies to enable precise targeting of resistant tumours.

Kayentis is a global leader in electronic clinical outcome assessment (eCOA) and Decentralized Clinical Trial solutions, focused on enhancing the efficiency and quality of data collection in clinical trials for the pharmaceutical, biotech, and contract research organization sectors. Founded in 2005, the company has specialized in eCOA solutions across various phases of clinical development, addressing over 200 indications in more than 20 therapeutic areas. Kayentis has adapted to the evolving clinical research landscape by offering a comprehensive suite of services aimed at supporting science-driven and patient-centric approaches. With operational capabilities spanning the USA, Europe, and Asia, Kayentis provides a range of adaptable tools to streamline electronic data capture, simplifying the clinical trial process for both patients and research sites.

GenoMines is a company focused on sustainable mining through innovative biological methods. It specializes in using plant-based technologies to extract critical metals from soils that are below traditional cut-off grades. By genetically enhancing hyperaccumulator plants, GenoMines leverages nature's ability to absorb metals, thereby not only sustainably mining these resources but also depolluting soils and increasing the availability of agricultural sites. This approach addresses significant environmental and societal challenges associated with conventional mining methods, aiming to support the transition to green energy in a responsible manner.

AlgoTherapeutix develops topical treatments for complex pain conditions, focusing on chemotherapy-induced peripheral neuropathy and diabetic neuropathic pain. The company repurposes existing drugs to target damaged nerve fibers in the skin, avoiding systemic side effects of oral drugs.

Founded in Paris, France in 2012, PILI Inc. specializes in the research and manufacture of bio-fabricated colors using microorganisms. The company designs enzymes and fermentation biotechnologies to efficiently transform sugar into renewable and long-lasting dyes and pigments.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in research and development of medicines that utilize both botanical and pharmaceutical agents to aid individuals attempting to quit smoking. Its primary product, NFL-101, is a clinically developed botanical drug designed specifically to target smoking addiction. This innovative treatment contains minimal amounts of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a unique approach to support smokers in overcoming their addiction.

Ecoat develops and manufactures bio‑based binders and coatings that reduce the carbon footprint of the paint and coating industry. Its product line includes water‑based, bio‑based alkyd emulsions, tension‑free specialty oils, and urethane‑modified alkyd emulsions, as well as air‑purifying emulsions and other specialty products such as secoia and inokem. The company supplies these sustainable binders to manufacturers of architectural, wood, and metal protective coatings, allowing them to produce eco‑friendly paints and varnishes without sacrificing performance.

BiPER Therapeutics is a biotechnology company focused on developing innovative therapeutics, particularly targeting key proteins involved in cancer cell survival and treatment resistance. Its primary focus is on gastrointestinal cancers.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in research and development of medicines that utilize both botanical and pharmaceutical agents to aid individuals attempting to quit smoking. Its primary product, NFL-101, is a clinically developed botanical drug designed specifically to target smoking addiction. This innovative treatment contains minimal amounts of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a unique approach to support smokers in overcoming their addiction.

Mycophyto, co-founded in July 2016 by Justine Lipuma, a microbiology PhD, and Christine Poncet-Doiset, a Senior Research Engineer at INRA, focuses on innovative solutions for agricultural systems. Drawing on 30 years of research in biological crop protection, the company specializes in developing customized products and support services aimed at enhancing plant growth through the use of indigenous fungi and soil pathogens. Mycophyto operates an inbuilt greenhouse where it cultivates these beneficial microorganisms, allowing plant researchers to cultivate crops, herbs, and other plants without reliance on chemical fertilizers. This approach not only promotes sustainable agricultural practices but also contributes to healthier ecosystems.

ErVaccine Technologies creates immunotherapies that integrate T-cell treatments with cancer vaccinations to meet a medical need for cold tumors. They are committed to identifying tumor epitopes that are physician. They come from endogenous retroviruses and are novel cancer epitopes. They use a bioinformatics-based strategy to find possible epitopes, which are then verified by proteomics and immunological testing.

Remedee Labs SAS is a French company founded in 2016, dedicated to developing innovative solutions for chronic pain management. The company has created the Microelectronic Endorphin Trigger (MEET), a personal endorphin stimulator that facilitates on-demand stimulation of the body’s natural endorphins to alleviate pain. Drawing on a decade of pre-clinical and clinical research, Remedee Labs aims to improve the quality of life for the 1.5 billion people worldwide suffering from chronic pain, particularly focusing on conditions such as fibromyalgia. By collaborating with medical practitioners, the company offers a patient-centered digital service platform that enhances the accessibility and effectiveness of endorphin-stimulation therapy for personal healthcare. As it continues to evolve, Remedee Labs plans to expand its platform to address additional chronic pain conditions, positioning itself as a leader in neuromodulation technology for pain management.

Jalon Therapeutics is a biotechnology company focused on developing cancer therapies by inactivating essential tumor signaling pathways through disruption of protein-protein interactions. The company aims to identify novel therapeutic targets, including through non-oncogene addiction, and to develop anticancer treatment strategies that advance patient outcomes.

Founded in 2013, Meccellis Biotech specializes in the development of biological implants for tissue repair. Utilizing tissue and cellular engineering, they offer solutions tailored to various surgical specialties.

Microphyt is a company focused on researching, developing, producing, and marketing natural algae-based products. It specializes in creating bioactive dietary supplements aimed at promoting weight loss and supporting brain health. The company utilizes an industrial-scale supply of microalgae biomass and extracts, ensuring the preservation of cell integrity while achieving commercial quantities of slow-growing or biofilm-forming species. This approach enables Microphyt to effectively cater to the demands of healthcare industries, particularly in the personal care and food sectors.

Biomemory is a deep-tech company focusing on innovative data storage solutions for large enterprises and institutions. It leverages molecular engineering to create cost-effective, energy-efficient appliances that enable exabyte-scale storage. The company's advanced data storage drives utilize a biobased system that encodes substantial amounts of data on long DNA strands, significantly surpassing the capacity of traditional storage methods such as solid-state drives and magnetic tapes. Biomemory's technology offers remarkable durability, ensuring data stability at ambient temperatures without the need for energetic input or CO2 emissions, making it an environmentally friendly choice. This approach provides researchers and organizations with a long-lasting storage solution, capable of preserving information for thousands of years.

Lys Therapeutics is a biotechnology company focused on developing therapies for patients with neurovascular and neurodegenerative disorders. The company is notable for its lead drug, Glunozumab, a monoclonal antibody that employs a novel mechanism of action. This drug hyperactivates both vascular and neuronal NMDA receptors, leading to off-target toxicity that can disrupt the blood-brain and blood-spinal cord barriers, resulting in neuronal excitotoxicity associated with conditions such as stroke and multiple sclerosis. Lys Therapeutics aims to address neuroinflammation and its effects on neurodegeneration through innovative biotherapies.

Valneva is a vaccine company focused on developing prophylactic vaccines for infectious diseases with significant unmet medical needs. It has successfully commercialized two vaccines, IXIARO/JESPECT and DUKORAL, and is advancing candidates against Lyme disease, chikungunya virus, and COVID-19.

BioMAdvanced Diagnostics is a company focused on developing molecular diagnostic and biomarker tests that enhance patient care through individualized treatment strategies. Their innovative tests are designed to integrate seamlessly into existing diagnostic and treatment protocols, ensuring ease of use for healthcare personnel. By providing predictive scores and identifying biomarkers, BioMAdvanced Diagnostics enables clinicians to assess the immune response of patients and evaluate the risk of transplant rejection. This capability allows for improved anticipation and adaptation of treatment plans, ultimately aiming to enhance patient outcomes significantly.

Tridek-One is a biotechnology company focused on developing immunomodulatory products aimed at addressing auto-immune and inflammatory disorders. The company's primary product is a peptide designed to maintain a cluster of truncated CD31 molecules at the membrane, which helps moderate overactive immune responses without complete blockade. By facilitating improved treatment options for medical companies, Tridek-One seeks to enhance the quality of life for patients suffering from these conditions.

SparingVision SAS is a biotechnology company based in Paris, France, dedicated to discovering and developing gene therapy-based treatments for inherited retinal diseases that can lead to blindness. Founded in 2016, the company is focused on creating innovative therapies for conditions such as retinitis pigmentosa, the most prevalent form of inherited retinal degeneration, which currently lacks comprehensive treatment options. SparingVision is advancing its lead candidate, SPVN06, which aims to address the needs of the nearly 2 million individuals affected by this rare genetic disorder globally. By targeting the underlying causes of these diseases, SparingVision seeks to improve the quality of life for patients suffering from genetic retinal disorders.

Apmonia Therapeutics develops peptide-based therapies targeting the tumor microenvironment to improve cancer patient outcomes. Their focus includes glioblastoma, ovarian, colorectal, and pancreatic cancers.

Carroucell is a supplier of microcarriers specifically designed for cell culture in bioreactors. The company has developed a unique platform featuring flat-shaped microcarriers made from a glass xenofree composition. This innovative design aims to enhance the efficiency of biomanufacturing by addressing common challenges associated with cell culture performance. Through its specialized products, Carroucell supports advancements in the field of cell culture, contributing to the overall improvement of biotechnological processes.

Founded in 2019, DeepLife is a biotechnology company based in Paris, France. It specializes in developing digital twins of cells to accelerate drug discovery. The company uses advanced modeling techniques and deep learning on multi-omics data to simulate cell responses and identify new targets, biomarkers, and potential drug candidates.

Øzers is a French foodtech company that specializes in developing innovative sports nutrition products that prioritize both performance and health. Led by a professional boxer and engineer, the company collaborates with biotech engineers and medical professionals to create formulations that utilize only healthy, plant-based ingredients. Its offerings include ultra-functional edible supplements made from vegetable proteins, microalgae, vitamins, and minerals. By focusing on the benefits of natural components, Øzers aims to help athletes optimize their performance without compromising their health.

Thabor Therapeutics is a biotechnology company focused on developing innovative treatments for mucosal inflammatory diseases. The company targets a new class of proteins involved in inflammation resolution, aiming to inhibit specific processes in the early stages of inflammation and the recruitment of innate immune cells. By leveraging monoclonal antibodies, Thabor Therapeutics seeks to provide effective solutions for healthcare providers to treat patients suffering from these conditions.

Phagos develops personalized bacteriophage solutions as a sustainable alternative to antibiotics.

Healshape is a biotech startup dedicated to developing natural breast reconstruction solutions for women through innovative regenerative medicine techniques. The company specializes in creating bioprostheses using 3D bioprinting technology, offering an alternative to traditional breast reconstruction methods. By focusing on natural products, Healshape aims to provide women with long-lasting, aesthetically pleasing results, helping them regain their self-confidence following surgery.

Osivax develops immunotherapy vaccines designed to enhance the body's immune response against infectious diseases. Their vaccines aim to expedite uptake into dendritic cells and increase immunogenicity of natural proteins, triggering a more effective immune response, including CD8 T cell activation. This enables medical practitioners to treat patients with conditions such as cancer, influenza, malaria, and other infectious diseases.

DBV Technologies is a clinical-stage biopharmaceutical company focused on epicutaneous immunotherapy, delivering biologically active compounds to the immune system through the skin using its Viaskin platform. Its lead product candidate, Viaskin Peanut, targets peanut allergy and is advancing for use in children aged 4 to 11 and other age groups. The company is developing Viaskin Milk for immunotherapy of cow’s milk protein allergy and milk-induced eosinophilic esophagitis, Viaskin Egg in preclinical development for egg allergy, and a booster vaccine for Bordetella pertussis. Additional early-stage programs include efforts against respiratory syncytial virus, Crohn’s disease, celiac disease, and type 1 diabetes. DBV Technologies has collaborations to expand its diagnostic capabilities, including a patch-based test with Nestlé Health Science for non-IgE mediated CMPA. Founded in 2002 and headquartered in Montrouge, France, the company emphasizes skin-delivered immunotherapy as its core approach.

Hemerion Therapeutics specializes in developing innovative cancer treatments, with a primary focus on advanced methods for treating glioblastoma, the most common and aggressive form of primary brain tumour. The company's proprietary platform combines photosensitizing molecules with advanced laser light technologies to enable precise targeting of resistant tumours.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer. The firm focuses on creating a pipeline of small molecules that specifically target the eukaryotic translation initiation factor-4A to address resistance in patients who have become unresponsive to existing targeted therapies. With a primary emphasis on melanoma, Ribonexus aims to enhance the effectiveness of current treatments by restoring sensitivity to them in patients whose cancers have developed resistance. Through its research and development efforts, Ribonexus seeks to contribute meaningful advancements in oncology and improve treatment outcomes for patients facing challenging cancer types.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer. The firm focuses on creating a pipeline of small molecules that specifically target the eukaryotic translation initiation factor-4A to address resistance in patients who have become unresponsive to existing targeted therapies. With a primary emphasis on melanoma, Ribonexus aims to enhance the effectiveness of current treatments by restoring sensitivity to them in patients whose cancers have developed resistance. Through its research and development efforts, Ribonexus seeks to contribute meaningful advancements in oncology and improve treatment outcomes for patients facing challenging cancer types.

Phagos develops personalized bacteriophage solutions as a sustainable alternative to antibiotics.

LimFlow is a medical technology company focused on developing innovative solutions for treating end-stage chronic limb ischemia (CLI) patients. Its flagship product, the LimFlow System, utilizes a novel percutaneous procedure to restore blood flow to the ischemic foot by diverting blood around diseased arteries into the tibial vein. This approach is designed to provide an elevated flow of oxygenated blood, thereby alleviating ischemic pain, promoting wound healing, reducing the risk of amputations, and enhancing patient mobility. Currently approved for sale in CE-mark regulated markets, the LimFlow System is also undergoing investigational use in the United States, where it offers new hope to patients who have exhausted other revascularization options. LimFlow emphasizes a multi-disciplinary team approach to maximize the benefits of its technology.

Priothera is a clinical-stage biotechnology company developing orally administered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company focuses on reducing the egress of T cell subsets from lymphatic tissue to enhance the curative potential of allogeneic hematopoietic stem cell transplantation, enabling dual inhibition of graft-versus-host disease while strengthening graft-versus-leukemia effects. Its lead program, mocravimod, aims to improve outcomes for patients undergoing HSCT. Priothera was incorporated in 2020 and is based in Dublin, Ireland, with an additional location in Saint Louis, France.

Vaxxel is a biotechnology company focused on developing live-attenuated vaccines. Its innovative platform aims to create novel vaccines targeting critical respiratory diseases such as bronchiolitis and pneumonia, specifically caused by human metapneumovirus.

Brenus Pharma develops allogeneic cell-based immunotherapies for solid tumors. The company creates allogeneic cell vaccines to empower immune cells in vivo to recognize and attack cancer, by mimicking tumor properties and increasing visibility to the immune system. Its platform aims to educate the immune system to anticipate relapse mechanisms by stimulating selected tumor cell lines, enabling clinicians to induce responses during chemotherapy or radiotherapy. The approach seeks to prevent cancer resistance to treatment and improve durability of responses across solid tumors.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

CarbonWorks specializes in harnessing microalgae to capture and utilize carbon dioxide. It develops photobioreactors that convert industrial emissions into valuable biomass for agricultural biocontrol and animal feed, enabling industries to produce safe bioproducts at scale while reducing their carbon footprint.

Founded in 2017 and based in Toulouse, France, Cell-Easy operates as a stem cell Contract Development and Manufacturing Organization (CDMO). It specializes in providing ready-to-inject adipose-derived allogeneic stem cells for preclinical and clinical development projects.